- Home
- ORGN vs ANEB Comparison
ORGN vs ANEB Comparison
Compare ORGN & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGN | ANEB |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.4M | 96.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORGN | ANEB |
|---|---|---|
| Price | $0.28 | $2.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 21.7K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,122,000.00 | N/A |
| Revenue This Year | $49.18 | N/A |
| Revenue Next Year | $144.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.80 |
| 52 Week High | $1.36 | $3.42 |
Technical Indicators
Market Signals| Indicator | ORGN | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 20.87 | 41.98 |
| Support Level | $0.43 | $1.91 |
| Resistance Level | $0.46 | $2.40 |
| Average True Range (ATR) | 0.04 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 4.71 | 51.77 |
Price Performance
Historical ComparisonAbout ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.